samedan logo
 
 
spacer
home > ebr > spring 2004 > reproducible, low cost arraying achieved with a multiplexed approach
PUBLICATIONS
European BioPharmaceutical Review

Reproducible, Low Cost Arraying Achieved with a Multiplexed Approach

Microarrays: A Powerful but Imperfect Tool

Microarrays are well-recognised as powerful tools, that enable the global characterisation of physiological state at the genomic level (1-3). However, the widespread use of microarrays outside basic research is hindered by high costs, inadequate reproducibility (4) and bioinformatic limitations (5). Such problems have resulted in barriers for the implementation of this technology in clinical diagnostic applications, which is arguably the logical 'endpoint' for microarray analysis/acceptance (6,7).

Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Samuel D Conzone, Manager of Research and Development and Dr Rajendra J Redkar, R&D Scientist, at Schott Nexterion

Dr Samuel D Conzone obtained his BSc degree from Alfred University, New York in 1994 with a BSc in Ceramic Science. He then attended the University of Missouri-Rolla, conducting research on biodegradable, radioactive glass microspheres intended for the in vivo treatment of ailments such as liver cancer and rheumatoid arthritis. He received his PhD in Ceramic Engineering in June 1999, and his research work was rewarded with the Norbert J Kreidl award for excellence in the area of glass science. Dr Conzone then proceeded to begin his career at Schott Glass Technologies (Duryea, PA) as an R&D Developmental Scientist, before becoming the Manager of Research and Development for Schott Nexterion activities in 2002. Dr Conzone is currently the author or co-author of 20 publications and 13 patents/patent applications.


Dr Rajendra J Redkar obtained his BSc and MSc degrees from the University of Poona, India in Microbiology. After working in the biotechnology industry for 10 years he attended Auburn University, USA, and conducted research in understanding the gene expression changes under NaCl-stress using Aspergillus nidulans as a model system. Dr Redkar received his PhD in Microbiology/Molecular Biology in April 1995. He then began his career at the University of Scranton, USA as a Research Scientist, and developed DNA-based diagnostic assays for pathogens and co-ordinated genome sequencing projects. In June 2001, he joined Schott Nexterion as an R&D Scientist and supported the development of coated slides for microarray applications. Dr Redkar has authored or co-authored 18 publications in peer-reviewed journals.

spacer
Dr Samuel D Conzone
spacer
spacer
spacer
Dr Rajendra J Redkar
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

FT Global Pharmaceutical and Biotechnology Conference 2008

2-3 December 2008, The Cumberland, London

FT Global Pharmaceutical and Biotechnology Conference is Europe’s pre-eminent industry event attended by leading executives, government decision makers, investors, analysts and other specialist providers. It provides a unique platform to present new perspectives,’ feel the pulse’ of the industry, and network with peers across the sector.
More info >>

 
News and Press Releases

Azopharma Product Development Group, Inc

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement